In addition to presenting several posters related to OINDP analysis, Melbourn Scientific will also be introducing a new Qualified Person (QP) services at the upcoming American Association of Pharmaceutical Scientists (AAPS) annual meeting. The 2011 meeting will be the first AAPS annual meeting attended by Melbourn, marking the UK company’s increased presence in the US market.
“We have had interest from US companies in using our analysis and Qualified Person (QP) services to certify batches of medicinal products prior to release for sale within the European Economic Area,” explains Melbourn CEO Mark Hammond.
The company recently doubled its laboratory space as part of an aggressive expansion, and Hammond notes that: “We were awarded an MIA (IMP) licence earlier this year and this adds significant value to our portfolio of services. As well as our traditional core offerings of analysis and formulation development we can also provide small-scale production and have a QP available to release the product for use in clinical trials. For overseas clients this service can shave valuable time from the development process and enable rapid development of the drug to reach the clinic in a more efficient manner.”
The company will present posters at AAPS describing work on three different aspects of inhaled product analysis: cooling of the Next Generation Impactor (NGI), the use of the Alberta Throat cascade induction port, and the role of laser diffraction in nebulizer development.
Read the Melbourn Scientific press release.
